Need Help?
No Article Versions Notes Found
Cite
Younus, J.; Verma, S.; Franek, J.; Coakley, N.; the Sarcoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. Sunitinib Malate for Gastrointestinal Stromal Tumour in Imatinib Mesylate–Resistant Patients: Recommendations and Evidence. Curr. Oncol. 2010, 17, 4-10. https://doi.org/10.3747/co.v17i4.560
Younus J, Verma S, Franek J, Coakley N, the Sarcoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. Sunitinib Malate for Gastrointestinal Stromal Tumour in Imatinib Mesylate–Resistant Patients: Recommendations and Evidence. Current Oncology. 2010; 17(4):4-10. https://doi.org/10.3747/co.v17i4.560
Chicago/Turabian StyleYounus, J., S. Verma, J. Franek, N. Coakley, and the Sarcoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. 2010. "Sunitinib Malate for Gastrointestinal Stromal Tumour in Imatinib Mesylate–Resistant Patients: Recommendations and Evidence" Current Oncology 17, no. 4: 4-10. https://doi.org/10.3747/co.v17i4.560
APA StyleYounus, J., Verma, S., Franek, J., Coakley, N., & the Sarcoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. (2010). Sunitinib Malate for Gastrointestinal Stromal Tumour in Imatinib Mesylate–Resistant Patients: Recommendations and Evidence. Current Oncology, 17(4), 4-10. https://doi.org/10.3747/co.v17i4.560
